Multiparameter prediction of myeloid neoplasia risk
Muxin Gu(Wellcome/MRC Cambridge Stem Cell Institute), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), Clea Bárcena(Universidad de Oviedo), William G. Dunn(Wellcome/MRC Cambridge Stem Cell Institute), Irina Mohorianu(Wellcome/MRC Cambridge Stem Cell Institute), Margarete A. Fabre(AstraZeneca (United Kingdom)), Luca Malcovati(University of Pavia), Siddhartha Kar(At Bristol), Catherine Cargo(St James's University Hospital), Alexandra Smith(University of York), Moritz Gerstung(European Bioinformatics Institute), Sruthi Cheloor Kovilakam(Wellcome/MRC Cambridge Stem Cell Institute), Pedro M. Quirós(École Polytechnique Fédérale de Lausanne)
Cited by 107
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k